Can Jisandai (Bingtonsha) completely eliminate hepatitis C virus?

Epclusa (Epclusa) is an oral antiviral drug widely used to treat chronic hepatitis C virus (HCV) infection. It consists of sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir). Sofosbuvir is an NS5B polymerase inhibitor, and velpatasvir is an NS5A NS5A inhibitor. The two ingredients work synergistically to effectively inhibit the replication and spread of hepatitis C virus. Jisanda (Bingtonsa)is approved for the treatment of all six genotypes of HCV and is currently the only hepatitis C drug that is not restricted by viral genotypes.

In clinical trials, Jisandai (Bingtonsa) showed an extremely high cure rate (SVR12), that is, after completing 12 weeks of treatment, the hepatitis C virus RNA was undetectable in the patient's body. Data show that the cure rate of Jisanda (Bingtonsa) is usually above 95%, and the cure rates of different genotypes are slightly different, but in general, Jisanda (Bingtonsa) is very effective in eliminating hepatitis C virus.

Although Jisandai (Bingtonsa) performs well in treating hepatitis C, whether it can completely eliminate the hepatitis C virus depends on many factors. Factors such as the patient's degree of cirrhosis, viral load, previous treatment history, and comorbidities may affect the effectiveness of treatment. For example, patients with cirrhosis have a relatively low cure rate, while patients with relatively good liver function have a higher cure rate. In addition, some special circumstances, such as patients being resistant to drugs or having other underlying diseases, may also affect the efficacy of Jisandai (Bingtonsa).

The usage method of Jisandai (Bingtonsha) is to take one tablet once a day for 12 consecutive weeks. In some cases, such as in patients with decompensated cirrhosis, glycerin may need to be combined with ribavirin to improve efficacy. During treatment, patients should undergo regular blood tests to monitor viral load and liver function, and adjust the treatment plan under the guidance of a doctor.

Although the cure rate of Jisanda (Bingtonsa) is very high, in a few cases, patients may experience relapse of the virus after treatment. To reduce the risk of recurrence, patients should take medications strictly as prescribed by their doctor and undergo regular follow-up testing after treatment.